Showing posts with label progression-free survival (PFS). paclitaxel or docetaxel. Show all posts
Showing posts with label progression-free survival (PFS). paclitaxel or docetaxel. Show all posts
Tuesday, January 15, 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

›
In continuation of my update on  carboplatin and a taxane Morphotek ®  Inc., a wholly-owned subsidiary of Eisai Inc., announced top...